Navigation Links
Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
Date:11/29/2007

NATICK, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the recommendation of a U.S. Food and Drug Administration (FDA) advisory panel to approve with conditions the PROMUS(TM) / XIENCE(TM) V everolimus-eluting coronary stent system. The PROMUS and XIENCE V stent systems are identical products, sold respectively by Boston Scientific and Abbott in international markets. Both stent systems would be covered by the same FDA approval.

"Today's recommendation is a significant step toward making Boston Scientific's two-drug program a reality in the United States," said Hank Kucheman, Senior Vice President and President of Boston Scientific's Cardiovascular business. "Once approved in the United States, the PROMUS stent system -- together with our proven and market-leading TAXUS stent technology -- will enable Boston Scientific to offer physicians and their patients a choice of two distinct drugs, each on a highly deliverable stent platform."

The PROMUS and XIENCE V stent systems are investigational devices in the U.S. and not yet approved for sale. PROMUS is a private-labeled XIENCE V everolimus-eluting stent system manufactured by Abbott and distributed by Boston Scientific.

TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

617-459-2703 (mobile)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces Amended Agreement to Settle Product Lawsuits
7. Boston Scientific Announces New Initiatives to Increase Shareholder Value
8. Boston Scientific Announces Additions to Clinical Sciences Organization
9. Boston University School of Medicine physician receives award from AATOD
10. Boston Scientific Announces Verdict in Cordis Litigation
11. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home Health, an ... two personal care service companies: Padre Home Health in Corpus Christi, Texas, and ... , Well regarded in their respective markets, these two agencies align with Texas ...
(Date:1/24/2017)... Clara, CA (PRWEB) , ... January 23, 2017 ... ... announces the launch of a new plugin that allows sleep centers to automatically ... Sleep Device Interface (SDI)—is a thin client browser plugin is quickly installed on ...
(Date:1/23/2017)... ... January 23, 2017 , ... PKF O’Connor Davies ... J. Nelson, a senior accountant at the Firm, will participate in the 40th Annual ... Over 200 runners will race up 1,576 steps, a vertical distance equal to about ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, ... technology behind SmartCap, which was founded in 2008 to address the limitations of ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted for $3,702.2 ... grow at a CAGR of 6.0% during 2016-2022. The ... in the global market between the two types in ... segment accounted for the highest share in the global ... catheter market is witnessing high growth rate, due to ...
(Date:1/24/2017)... CHICAGO , January 23, 2017 ... solutions for life sciences, announces agClinical 3.3, the latest ... release further enables life science organizations to confidently and ... monitoring and better manage the electronic trial master file ... ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
Breaking Medicine Technology: